8-K: Arbutus Biopharma to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma announces the acceptance of five abstracts, including one late-breaker, for presentation at the European Association for the Study of the Liver (EASL) Congress 2025.

Summary

• Arbutus Biopharma will present data on Imdusiran and AB-101 at the EASL Congress 2025 in Amsterdam from May 7-10, 2025.
• Five abstracts have been accepted for poster presentations, including one late-breaker.
• The presentations will cover the IM-PROVE I study, which examines chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after Imdusiran treatment.
• Additional data will be presented on AB-101, an oral small-molecule PD-L1 inhibitor, including its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy and CHB subjects.
• A late-breaker poster will present data on the off-treatment antiviral efficacy and safety of repeat dosing of Imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed CHB subjects.

Sentiment

Score: 7

Explanation: The announcement is positive as it highlights the progress of Arbutus's pipeline and upcoming presentations at a major scientific conference. However, it is still early-stage clinical data, and the risks associated with drug development remain.

Positives

• Imdusiran has shown meaningful functional cure rates in patients with cHBV when combined with pegylated interferon (IFN) alfa-2 and nucleos(t)ide analogue (NA) therapy in a Phase 2a clinical trial.
• AB-101 was safe and well-tolerated in healthy subjects in Phase 1 trials.
• AB-101 demonstrated dose-responsive increases in PD-L1 receptor occupancy in peripheral blood cells.
• Preclinical data suggests AB-101 can reactivate exhausted HBV-specific T-cells from cHBV patients.

Risks

• Clinical trials may be more costly or take longer to complete than anticipated.
• Arbutus may change its strategy regarding its product candidates and clinical development activities.
• Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus products.
• Economic and market conditions may worsen, impacting Arbutus's operations and development plans.
• Market shifts may require a change in strategic focus.

Future Outlook

Arbutus is reviewing development plans for a Phase 2b clinical trial of Imdusiran combined with IFN and NA therapy, and AB-101 is currently being evaluated in a Phase 1a/1b clinical trial.

Industry Context

The presentations at EASL Congress 2025 highlight Arbutus's ongoing efforts to develop novel therapies for chronic hepatitis B, a significant global health challenge with limited treatment options. The company is exploring both RNAi-based approaches (Imdusiran) and immune checkpoint inhibitors (AB-101) to achieve functional cure.

Comparison to Industry Standards

• Arbutus's Imdusiran, an RNAi therapeutic, is comparable to other HBV-targeting RNAi therapies in development by companies like Dicerna Pharmaceuticals (acquired by Novo Nordisk) and Arrowhead Pharmaceuticals.
• AB-101, an oral PD-L1 inhibitor, aims to provide a safer alternative to antibody-based immune checkpoint inhibitors, which can have systemic safety issues.
• The IM-PROVE I study's focus on functional cure aligns with the industry's goal of achieving long-term remission of HBV infection.
• The combination of Imdusiran with interferon and nucleos(t)ide analogues is a strategy similar to those being explored by other companies to enhance treatment efficacy.

Stakeholder Impact

• Positive for shareholders as it indicates progress in the company's drug development programs.
• Potentially positive for patients with chronic hepatitis B if the therapies prove effective and safe.
• May have a positive impact on employees as the company advances its clinical programs.

Next Steps

• Arbutus will present the accepted abstracts at the EASL Congress 2025 from May 7-10, 2025.
• The company is reviewing development plans for a Phase 2b clinical trial of Imdusiran.
• AB-101 is currently being evaluated in a Phase 1a/1b clinical trial.

Key Dates

Keywords

Arbutus Biopharma, EASL Congress 2025, Imdusiran, AB-101, Hepatitis B, HBV, RNAi, PD-L1 inhibitor, Clinical trials, Abstracts, Presentations